Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 9/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1129424 | 0.85 | CYP1A2 (0.57) | PDE7ATP53SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL1129585 | 0.85 | PDE7A (0.73) | PDE7ATP53SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL18239988 | 0.80 | PDE7A (1.00) | PDE7ASMN1; SMN2ALDH1A1TSHRPDE7B | |
| SCHEMBL1129535 | 0.78 | ALDH1A1 (0.49) | TP53SMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL18239974 | 0.76 | PDE7A (0.85) | PDE7ASMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL1129576 | 0.75 | ALDH1A1 (0.60) | PDE7ATP53MAPTALDH1A1LMNA | |
| SCHEMBL18239989 | 0.75 | PDE7A (1.00) | PDE7ATP53SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL15195139 | 0.73 | PDE7A (0.68) | PDE7ASMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL8986839 | 0.73 | PDE7A (0.68) | PDE7ASMN1; SMN2ALDH1A1LMNATSHR | |
| SCHEMBL5026021 | 0.73 | PDE7A (0.79) | PDE7ASMN1; SMN2MAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160231-A1 | DIHYDROOROTATE DEHYDROGENASE AS ANTIFUNGAL DRUG TARGET AND QUINAZOLINONE-BASED INHIBITORS THEREOF | F2G LIMITED (GB) | 2011-06-30 | — | — | US | claimed |
| EP-2283151-A2 | DIHYDROOROTATE DEHYDROGENASE AS ANTIFUNGAL DRUG TARGET AND QUINAZOLINONE-BASED INHIBITORS THEREOF | F2G Limited (GB) | 2011-02-16 | — | — | EP | claimed |
| WO-2009133379-A2 | ANTIFUNGAL TARGET | F2G LIMITED (GB) | 2009-11-05 | — | — | WO | claimed |
| EP-2283151-B1 | DIHYDROOROTATE DEHYDROGENASE AS ANTIFUNGAL DRUG TARGET | F2G LTD (GB) | 2017-03-08 | — | — | EP | disclosed |
| US-9034887-B2 | Dihydroorotate dehydrogenase as antifungal drug target and quinazolinone-based inhibitors thereof | F2G LIMITED (GB) | 2015-05-19 | — | — | US | disclosed |
| US-20110160231-A1 | DIHYDROOROTATE DEHYDROGENASE AS ANTIFUNGAL DRUG TARGET AND QUINAZOLINONE-BASED INHIBITORS THEREOF | F2G LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| EP-2283151-A2 | DIHYDROOROTATE DEHYDROGENASE AS ANTIFUNGAL DRUG TARGET AND QUINAZOLINONE-BASED INHIBITORS THEREOF | F2G Limited (GB) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009133379-A2 | ANTIFUNGAL TARGET | F2G LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160231-A1 | DIHYDROOROTATE DEHYDROGENASE AS ANTIFUNGAL DRUG TARGET AND QUINAZOLINONE-BASED INHIBITORS THEREOF | DHODH, DHRS9, DLD | PDE7A 943/4885TP53 1452/4885SMN1; SMN2 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.